Thymic epithelial tumors are rare and mostly malignant human neoplasms charac- terized by a fascinating variety of morphological features and an unrivaled frequency of associated autoimmune diseases. As a consequence, a myriad of complex diagnostic and clinical problems ensues in patients with these tumors. Since only a few specialists in each country are familiar with these problems, this volume intends to summarize the state of the art of thymic epithelial tumor pathology and biology and treatment protocols. The vol- ume is also designed to promote the interaction between scientists from a variety of disci- plines and physicians treating thymoma patients. In the first part of the volume, morphological and immunohistological criteria are given for the various subtypes of thymic epithelial tumors. The two competing classifica- tions and nomenclature systems existing to date are jointly considered. In addition. mor- phological overlaps between organotypic and nonorganotypic thymic epithelial tumors are stressed, since they may have a major bearing on diagnostic and therapeutic strategies.
The second part of the volume is devoted to recent data on normal T-cell maturation and the impact of abnormal T-cell development in thymic epithelial tumors on the development of paraneoplastic autoimmunity. Multicolor flow cytometry. the human/SCI[}-mouse system, transgenic mouse technology, and T-cell cloning techniques have greatly contributed to this fascinating field of research.
Auflage
Softcover reprint of the original 1st ed. 1997
Sprache
Verlagsort
Zielgruppe
Für Beruf und Forschung
Research
Illustrationen
Maße
Höhe: 254 mm
Breite: 178 mm
Dicke: 23 mm
Gewicht
ISBN-13
978-1-4899-0035-7 (9781489900357)
DOI
10.1007/978-1-4899-0033-3
Schweitzer Klassifikation
I. Histological and Immunological Characterization of Thymic Epithelial Tumors and Their Differential Diagnoses.- 1. Classification of Thymic Epithelial Neoplasms.- 2. Thymic Carcinoma.- 3. Thymoma/Thymic Carcinoma: A Distinctive, Unusual Morphologic Entity.- 4. A Clinicopathological Study of Thymomas in Singapore.- 5. Thymoma: A Clinicopathologic Study of 60 Cases.- 6. p53-Alterations in Thymic Epithelial Tumors.- 7. p53 Protein Expression in Thymic Epithelial Tumors.- 8. p53 Overexpression and Thymoma Prognosis.- 9. Metallothionein Expression in Thymomas: A Tumor Marker for Spindle and Squamoid Thymoma Cells.- 10. Cytokeratin (CK) Profile in Thymomas: CK 10 Is a Marker for Cortical Thymomas and CK 20 a Marker for Medullary Thymomas.- 11. Neuroendocrine Differentiation in Thymic Epithelial Tumors: Immunohistochemical Studies.- 12. Microscopic Thymoma and Myasthenia Gravis: A Clinicopathological and Immunohistochemical Study of Two Cases.- 13. Complex and Differential Cytokeratin Profiles in Thymomas and Correlation with Normal Thymus.- 14. Unusual Recurrence of Mixed Thymoma in Breast.- 15. Histiocytosis -X of the Thymus: Development of Myelomonocytic Leukemia 5 Years after Thymectomy.- II. Altered T Cell Functions in Thymic Epithelial Tumors.- 16. T Cell Development in the Human Thymus.- 17. Intrathymic Autoantigens and Their Role in the Shaping of the Autoimmune T Lymphocyte Repertoire.- 18. T Cell Epitopes of the Acetylcholine Receptor and the Pathogenesis of Myasthenia Gravis.- 19. Thymus in Thymoma-Associated Myasthenia Gravis: Transplantation of Thymoma and Extrathymomal Thymic Tissue into SCID Mice.- 20. Thymic Tumor Progression in SV40T Transgenic Mice Model: Suggestion of Thymoma-Thymic Carcinoma Sequence.- 21. Analysis of a Murine Thymic CarcinogenesisModel Induced by the Expression of Large T of SV40.- 22. Inefficient Positive Selection of CD4+ T Cells in Epithelial Cell Tumors of the Human Thymus.- 23. Abnormal T Lymphocyte Development in Myasthenia Gravis-Associated Thymomas.- 24. Oligoclonal Peripheral T-Cell Lymphocytosis as a Result of Aberrant T-Cell Development in a Cortical Thymoma.- 25. Estrogens Modulate IL-6 Production by Cultured Normal and Pathological Human Thymic Epithelial Cells.- III. Paraneoplastic Autoimmunity.- 26. Thymoma and Autoimmune Neurological Disorders: A Search for Missing Links in Pathogenesis.- 27. T-Cell Derived Mechanisms in the Pathogenesis of Myasthenia Gravis.- 28. Thymomas Express Ryanodine Receptor Epitopes.- 29. Titin Epitope in Thymoma.- 30. Accessory Molecule Expression in Human Thymomas and Thymus.- 31. CD40-Expression in Thymoma.- 32. Myasthenia Gravis with Thymoma and Fas Antigen.- 33. Myasthenia Gravis Patients Have a Cellular Immune Response against Titin.- 34. Tumor Necrosis Factor Gene Polymorphisms in Thymoma and Non-Thymoma Myasthenia Gravis.- IV. Diagnosis and Therapy of Thymic Epithelial Tumors.- 35. Clinical Immunology of Thymic Tumors in Patients with Myasthenia Gravis.- 36. Myasthenia Gravis with Thymoma.- 37. Reproducibility of a Histogenetic Classification of Thymic Epithelial Tumours.- 38. Morphology of Thymic Remnants Removed after Video-Assisted Thoracoscopic Extended Thymectomy in Patients with Thymomatous Myasthenia Gravis.- 39. Core Needle Biopsy of Anterior Mediastinum Masses.- 40. Cyclin-Dependent Kinase 6 (PLSTIRE) Expression in Normal Thymus, Thymomas, and T-Cell Lymphoblastic Lymphoma.- 41. Our Approach in the Preparation for Thymectomy in Myasthenia Gravis.- 42. Onset of Myasthenia Gravis after Thymectomy for Thymoma.- V. Management of Thymectomized Patients.- 43. Aspects of Clinical Preparation of Thymectomy in Myasthenic Cases with or without Thymoma and the Clinico-Biological Follow-up of the Thymectomized Patients.- 44. Long-Term Prognosis of Patients with Thymoma-Associated Myasthenia Gravis.- 45. Thymoma and Myasthenia Gravis: Incidence of Tumor Recurrences in 126 Patients.- 46. Thymoma-Prognostic Factors and Outcome.- 47. Management of Thymectomised Myasthenic Patients.- 48. Management of Thymectomized Myasthenic Patients.- 49. Therapeutic Options in Locally Advanced Thymoma.- 50. The Role of Radiotherapy in Treatment of Thymoma.- Authors and Sponsors.
